Events & presentations

Upcoming Events
Date Event Details Remind Me
Nov 30, 2017
dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK
Email

dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK

Remind Me

Please sign up for Email alerts.


Dec 6–7, 2017
Citi 2017 Global Healthcare Conference, New York, NY, US
Email

Citi 2017 Global Healthcare Conference, New York, NY, US

Remind Me

Please sign up for Email alerts.


Dec 9–12, 2017
59th Annual American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA, US

Links to Abstracts

Daratumumab

Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase II Study

Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of POLLUX

Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study

Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in CASTOR

Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001): An Open-label, Phase Ib Study

Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Versus  Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients with Multiple Myeloma

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX, a Phase III Randomized Study

Daratumumab, Bortezomib and Dexamethasone  (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR

Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial

Cost-effectiveness of Daratumumab  Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial

Ofatumumab
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma After Prior Rituximab

Email

59th Annual American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA, US

Remind Me

Please sign up for Email alerts.


Dec 11, 2017
8:00 PM ET
2017 R&D Update, Atlanta, Georgia, US

Genmab (OMX: GEN, ADR: GMXAY) will hold its 2017 R&D Update on

Monday 11 December 2017 at 8:00 PM Eastern Time (2:00 AM CET / 1:00 AM GMT on 12 December)

The webcast event will include presentations by external key opinion leaders as well as Genmab speakers. A link to the webcast will appear on this page closer to the event. 

This meeting is NOT an official program of the ASH Annual Meeting.

Email

2017 R&D Update, Atlanta, Georgia, US

Remind Me

Please sign up for Email alerts.


Dec 14, 2017
DNB Nordic Healthcare Conference 2017, Oslo, Norway
Email

DNB Nordic Healthcare Conference 2017, Oslo, Norway

Remind Me

Please sign up for Email alerts.


Feb 21, 2018
After 5:00 PM CET
Publication of the Annual Report for 2017
Email

Publication of the Annual Report for 2017

Remind Me

Please sign up for Email alerts.


Apr 10, 2018
Annual General Meeting 2018
Email

Annual General Meeting 2018

Remind Me

Please sign up for Email alerts.


May 8, 2018
After 5:00 PM CET
Publication of the Interim Report for the first quarter 2018
Email

Publication of the Interim Report for the first quarter 2018

Remind Me

Please sign up for Email alerts.


Aug 8, 2018
After 5:00 PM CET
Publication of the Interim Report for the first half 2018
Email

Publication of the Interim Report for the first half 2018

Remind Me

Please sign up for Email alerts.


Nov 14, 2018
After 5:00 PM CET
Publication of the Interim Report for the first nine months 2018
Email

Publication of the Interim Report for the first nine months 2018

Remind Me

Please sign up for Email alerts.


Archived Events
Date Event Details
Nov 16–17, 2017
Bryan, Garnier & Co 5th Annual Healthcare Conference, Paris, France
Nov 15–16, 2017
Jefferies 2017 London Healthcare Conference, London, UK
Nov 9, 2017
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
Nov 8, 2017
6:00 PM CET
Third Quarter 2017 Conference Call
Nov 8, 2017
After 5:00 PM CET
Publication of the Interim Report for the first nine months 2017
Nov 4–7, 2017
2017 International Meeting of The European Society of Gynaecological Oncology (ESGO), Vienna, Austria
Sep 14, 2017
Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK
Sep 12, 2017
2:55 PM ET
Morgan Stanley Global Healthcare Conference, New York, NY, US
Sep 8–12, 2017
ESMO 2017 Congress, Madrid, Spain
Aug 10, 2017
2:00 PM CET
Interactive Q&A Session with Genmab's CEO
Aug 9, 2017
6:00 PM CET
Second Quarter 2017 Conference Call
Aug 9, 2017
After 5:00 PM CET
Publication of the Interim Report for the first half 2017
Jun 22, 2017
J.P. Morgan Cazenove European Healthcare Conference, London, UK
Jun 20–21, 2017
Citi 2017 European Healthcare Conference, London, UK
Jun 13, 2017
8:40 AM PT
Goldman Sachs 38th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US
Jun 2–6, 2017
ASCO Annual Meeting, Chicago, Illinois, US

To download presentations and select abstracts and posters please click here for our download library. 

Links to abstracts

Daratumumab


Randomized, open-label phase Ib/II study of atezolizumab with or without daratumumab in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study

Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status


Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX)

Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM)

Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR

Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR)

Comparative efficacy of multiple myeloma therapies for treatment of first relapse: A systematic literature review and network meta-analysis

Trends in survival and costs among US multiple myeloma patients

Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38

Ofatumumab

Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia

HuMax-AXL-ADC

GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817)
 

May 11, 2017
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
May 10, 2017
6:00 PM CET
First Quarter 2017 Conference Call
May 10, 2017
After 5:00 PM CET
Publication of the Interim Report for the first quarter 2017
Apr 19, 2017
10th Kempen & Co. Life Sciences Conference, Amsterdam, NL
Mar 28, 2017
Annual General Meeting 2017
Feb 28–Mar 1, 2017
Credit Suisse London One-on-One Healthcare Conference, London, UK
Feb 23, 2017
3:00 PM CET
Interactive Q&A Session with Genmab's CEO
Feb 22, 2017
6:00 PM CET
Full Year 2016 Conference Call